Phase I, Double-Blind, Randomized, Placebo-Controlled Trial to Examine the Safety, Tolerability and Plasma Pharmacokinetics of Increasing Single Oral Doses of TMC558445 With and Without Food, and Increasing Repeated Oral Doses in Combination With a Single Dose of TMC310911.
Phase of Trial: Phase I
Latest Information Update: 26 Apr 2010
At a glance
- Drugs Darunavir; TMC 310911; TMC 558445
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacokinetics
- 21 Nov 2009 Actual patient number (54) added as reported by ClinicalTrials.gov.
- 21 Nov 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 24 Jul 2009 Planned end date changed from 1 Jul 2009 to 1 Oct 2009 as reported by ClinicalTrials.gov.